SCHEMBL2901690

SCHEMBL2901690

C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)Cc1ccc2ccccc2c1)C(=O)N1C(=O)CCC(=O)[C@@]1(C(N)=O)C(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRD1 P41143 3/20 0.42
KISS1R Q969F8 2/20 0.38
SDCBP O00560 2/20 0.36
SDC2 P34741 2/20 0.36
PSMB8 P28062 1/20 0.36
CTSC P53634 1/20 0.36
DPP4 P27487 1/20 0.35
MME P08473 1/20 0.35
ACE P12821 1/20 0.35
CPA1 P15085 1/20 0.35
ACE2 Q9BYF1 1/20 0.35
MC4R P32245 2/20 0.35
MC3R P41968 2/20 0.35
MC1R Q01726 2/20 0.35
MMP9 P14780 4/20 0.34
FCER2 P06734 1/20 0.34
CTSB P07858 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
BACE1 P56817 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906422 0.88 OPRD1 (0.44) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2901655 0.85 OPRD1 (0.44) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2906563 0.84 OPRD1 (0.41) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2906899 0.79 OPRD1 (0.45) OPRD1KISS1RMMEACECPA1
SCHEMBL2906545 0.78 OPRD1 (0.39) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2906420 0.77 OPRD1 (0.48) OPRD1KISS1RSDCBPSDC2PSMB8
SCHEMBL2898235 0.76 PSMB1 (0.46) OPRD1PSMB8MMEACECPA1
SCHEMBL2905590 0.75 KISS1R (0.40) OPRD1KISS1RDPP4MMEACE
SCHEMBL2905764 0.72 OPRD1 (0.36) OPRD1KISS1RPSMB8DPP4MC4R
SCHEMBL5556869 0.70 OPRD1 (0.61) OPRD1SDCBPSDC2CTSCDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2239270-A2 Low molecular weight peptide derivatives as inhibitors of the Laminin/Nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2010-10-13 EP disclosed
EP-1845106-B1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction SANOFI AVENTIS DEUTSCHLAND (DE) 2010-08-11 EP disclosed
EP-1845106-A1 Low molecular weight peptide derivatives as inhibitors of the laminin/nidogen interaction Sanofi-Aventis Deutschland GmbH (DE) 2007-10-17 EP disclosed
EP-1157040-B1 LOW MOLECULAR WEIGHT PEPTIDE DERIVATIVES AS INHIBITORS OF THE LAMININ/NIDOGEN INTERACTION SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-22 EP disclosed
US-6365572-B1 FOR THERAPY OF DISEASES RELATED TO INCREASED OR UNWANTED SYNTHESIS OF BASEMENT MEMBRANES SUCH AS DIABETES MELLITUS; ATHEROSCLEROSIS; CANCER; DIABETIC RETINOPATHIA; FIBROPLASIA RETROLENTALIS; OR PSORIASIS, RHEUMATOIC ARTHRITIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-04-02 US disclosed